AVDL
AVADEL PHARMACEUTICALS-ADR
$8.66
Earnings Summary
Revenue | $17.55Mn |
Net Profits | $-8.61Mn |
Net Profit Margins | -49.02% |
Highlights
AVADEL PHARMACEUTICALS-ADR’s revenue fell -39.95% since last year same period to $17.55Mn in the Q2 2019. On a quarterly growth basis, AVADEL PHARMACEUTICALS-ADR has generated 6.8% jump in its revenue since last 3-months.
AVADEL PHARMACEUTICALS-ADR’s net profit fell -150.29% since last year same period to $-8.61Mn in the Q2 2019. On a quarterly growth basis, AVADEL PHARMACEUTICALS-ADR has generated 33.9% jump in its net profits since last 3-months.
AVADEL PHARMACEUTICALS-ADR’s net profit margin fell -316.77% since last year same period to -49.02% in the Q2 2019. On a quarterly growth basis, AVADEL PHARMACEUTICALS-ADR has generated 38.11% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the AVADEL PHARMACEUTICALS-ADR post its latest quarter earnings
EPS Estimate Current Quarter | -0.27 |
EPS Estimate Current Year | -0.27 |
Highlights
AVADEL PHARMACEUTICALS-ADR’s earning per share (EPS) estimates for the current quarter stand at -0.27 - a -1.45% fall from last quarter’s estimates.
AVADEL PHARMACEUTICALS-ADR’s earning per share (EPS) estimates for the current year stand at -0.27.
Key Ratios
Key ratios of the AVADEL PHARMACEUTICALS-ADR post its Q1 2023 earnings
Earning Per Share (EPS) | 0 |
Highlights
AVADEL PHARMACEUTICALS-ADR’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2023. This indicates that the AVADEL PHARMACEUTICALS-ADR has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2019-05-08 | -0.49 | -0.35 | 28.57% |
2019-11-12 | -0.27 | -0.24 | 11.11% |
2020-03-16 | -0.24 | -0.07 | 70.83% |
2019-08-09 | -0.29 | -0.23 | 20.69% |
Company Information
Avadel Pharmaceuticals plc is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Organisation | AVADEL PHARMACEUTICALS-ADR |
Headquarters | 10 Earlsfort Terrace, Dublin, Ireland, 2 |
Employees | 66 |
Industry | Health Technology |
CEO | Gregory Divis |
Discover More Earning Stocks in Health Technology Sector
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*